LI-COR Biotech: Odyssey M Chemi/Fluor Imaging Bundle Standard

The National Cancer Institute’s Laboratory of Human Carcinogenesis is seeking to acquire an Odyssey M Chemi/Fluor Imaging Bundle Standard to replace an aging and failing protein imaging system critical to ongoing and future intramural research. This equipment will serve as a shared resource across the laboratory and division, enabling a wide range of applications including fluorescent and colorimetric Western blots, In-Cell and On-Cell Western assays, ELISA, protein and nucleic acid arrays, high-resolution tissue section analysis, protein and nucleic acid detection, and non-isotopic Electrophoretic Mobility Shift Assays. The solicitation, numbered 75N91026Q00014, is issued by the Department of Health and Human Services under the office of the Assistant Secretary for Administration, with performance to occur in Bethesda, Maryland, and responses due by June 9, 2026. Submission must be completed electronically, and all offerors are required to have an active System for Award Management registration, a Unique Entity Identifier, a Dun & Bradstreet Number, a Taxpayer Identification Number, a valid CAGE code, and must certify their business size. Offerors must also complete the Security Prohibitions and Exclusions Representations and Certifications outlined in FAR 52.240-90 and FAR 52.240-91. Additional required documentation includes Attachment 2 with supplementary terms and conditions, and Attachment 4 containing NIH-specific invoicing instructions with IPP requirements. The procurement is classified under NAICS code 334516, and point of contact for inquiries is Shayna Simpson, with Rashiid Cummins as secondary contact.